- Home
- ODV vs YMAB Comparison
ODV vs YMAB Comparison
Compare ODV & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- YMAB
- Stock Information
- Founded
- ODV 2005
- YMAB 2015
- Country
- ODV Canada
- YMAB United States
- Employees
- ODV N/A
- YMAB N/A
- Industry
- ODV Precious Metals
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- YMAB Health Care
- Exchange
- ODV Nasdaq
- YMAB Nasdaq
- Market Cap
- ODV 338.9M
- YMAB 386.7M
- IPO Year
- ODV N/A
- YMAB 2018
- Fundamental
- Price
- ODV $2.54
- YMAB $8.52
- Analyst Decision
- ODV
- YMAB Buy
- Analyst Count
- ODV 0
- YMAB 11
- Target Price
- ODV N/A
- YMAB $15.02
- AVG Volume (30 Days)
- ODV 877.5K
- YMAB 1.7M
- Earning Date
- ODV 08-12-2025
- YMAB 08-08-2025
- Dividend Yield
- ODV N/A
- YMAB N/A
- EPS Growth
- ODV N/A
- YMAB N/A
- EPS
- ODV N/A
- YMAB N/A
- Revenue
- ODV $5,147,156.00
- YMAB $85,385,000.00
- Revenue This Year
- ODV $344.23
- YMAB N/A
- Revenue Next Year
- ODV $70.34
- YMAB $15.23
- P/E Ratio
- ODV N/A
- YMAB N/A
- Revenue Growth
- ODV N/A
- YMAB N/A
- 52 Week Low
- ODV $1.16
- YMAB $3.55
- 52 Week High
- ODV $2.75
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- ODV 58.94
- YMAB 81.55
- Support Level
- ODV $2.43
- YMAB $8.50
- Resistance Level
- ODV $2.65
- YMAB $8.53
- Average True Range (ATR)
- ODV 0.13
- YMAB 0.15
- MACD
- ODV 0.01
- YMAB 0.25
- Stochastic Oscillator
- ODV 77.60
- YMAB 99.54
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.